These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 35380004)
1. Development of a colorimetric assay for the detection of SARS-CoV-2 3CLpro activity. Garland GD; Harvey RF; Mulroney TE; Monti M; Fuller S; Haigh R; Gerber PP; Barer MR; Matheson NJ; Willis AE Biochem J; 2022 Apr; 479(8):901-920. PubMed ID: 35380004 [TBL] [Abstract][Full Text] [Related]
2. The SARS-CoV-2 main protease doesn't induce cell death in human cells in vitro. Komissarov A; Karaseva M; Roschina M; Kostrov S; Demidyuk I PLoS One; 2022; 17(5):e0266015. PubMed ID: 35609027 [TBL] [Abstract][Full Text] [Related]
3. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease. Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058 [TBL] [Abstract][Full Text] [Related]
4. Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2. Ferreira JC; Rabeh WM Sci Rep; 2020 Dec; 10(1):22200. PubMed ID: 33335206 [TBL] [Abstract][Full Text] [Related]
5. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro). Rothan HA; Teoh TC Mol Biotechnol; 2021 Mar; 63(3):240-248. PubMed ID: 33464543 [TBL] [Abstract][Full Text] [Related]
6. Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds. Zhu J; Zhang H; Lin Q; Lyu J; Lu L; Chen H; Zhang X; Zhang Y; Chen K Drug Des Devel Ther; 2022; 16():1067-1082. PubMed ID: 35450403 [TBL] [Abstract][Full Text] [Related]
7. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity. Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954 [TBL] [Abstract][Full Text] [Related]
8. Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor. O'Brien A; Chen DY; Hackbart M; Close BJ; O'Brien TE; Saeed M; Baker SC Virology; 2021 Apr; 556():73-78. PubMed ID: 33548599 [TBL] [Abstract][Full Text] [Related]
9. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862 [TBL] [Abstract][Full Text] [Related]
10. Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery. Grum-Tokars V; Ratia K; Begaye A; Baker SC; Mesecar AD Virus Res; 2008 Apr; 133(1):63-73. PubMed ID: 17397958 [TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development. Liu C; Boland S; Scholle MD; Bardiot D; Marchand A; Chaltin P; Blatt LM; Beigelman L; Symons JA; Raboisson P; Gurard-Levin ZA; Vandyck K; Deval J Antiviral Res; 2021 Mar; 187():105020. PubMed ID: 33515606 [TBL] [Abstract][Full Text] [Related]
12. A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. Novak J; Potemkin VA Mol Divers; 2022 Oct; 26(5):2631-2645. PubMed ID: 35001230 [TBL] [Abstract][Full Text] [Related]
13. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases. Chen CC; Yu X; Kuo CJ; Min J; Chen S; Ma L; Liu K; Guo RT FEBS J; 2021 Sep; 288(17):5089-5121. PubMed ID: 33400393 [TBL] [Abstract][Full Text] [Related]
17. Development of a deep learning-based quantitative structure-activity relationship model to identify potential inhibitors against the 3C-like protease of SARS-CoV-2. Kumari M; Subbarao N Future Med Chem; 2022 Nov; 14(21):1541-1559. PubMed ID: 36177879 [No Abstract] [Full Text] [Related]
18. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2. Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314 [TBL] [Abstract][Full Text] [Related]
19. Simple Nano-Luciferase-Based Assay for the Rapid and High-Throughput Detection of SARS-CoV-2 3C-Like Protease. Liu J; Ge C; Zha L; Lin L; Li R Anal Chem; 2023 Jan; 95(2):714-719. PubMed ID: 36576396 [TBL] [Abstract][Full Text] [Related]
20. Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors. Paul A; Sarkar A; Saha S; Maji A; Janah P; Kumar Maity T Bioorg Med Chem; 2021 Sep; 46():116301. PubMed ID: 34332853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]